No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 108.7x · 10Y median 105.0x · 53rd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 20
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:03:36.600Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Optimi Health Corp. (OPTH) stock was $4.20 as of Oct 6, 2026, 12:54 PM EDT, down 2.33% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -49.9% · 3-year avg +0.6%/yr · 5-year avg -21.8%/yr
Based in Princeton, Canada, Optimi Health Corp., established in 2020, is a Canadian entity focused on manufacturing pharmaceutical and nutraceutical products. The company produces and supplies controlled substances, including finalized MDMA and psilocybin drug products, directly to authorized clinics, pharmacies, research trials, and collaborative partners.
Drug Manufacturers - Specialty & Generic · Princeton, BC
Next Earnings Date
Feb 2, 2027
119 days away
EPS Estimate
-0.13
Revenue Est.
$189621.00
Last Quarter Results
EPS
$-0.40
vs Estimate
$-0.26
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1OPTH | $13.51M | $4.20 | -2.33% | -49.89% | -21.80% | N/A | N/A |
| 2HIND | $13.66M | $1.95 | +0.82% | -74.83% | -92.93% | N/A | vs OPTH |
| 3INAB | $13.71M | $1.43 | +0.70% | -40.44% | -62.88% | N/A | vs OPTH |
| 4CTXR | $13.78M | $0.50 | -3.48% | -61.87% | -60.04% | -46.34% | vs OPTH |
| 5PASG | $13.24M | $4.12 | +0.73% | -48.39% | -53.23% | N/A | vs OPTH |
| 6SINT | $13.92M | $2.19 | +0.46% | N/A | N/A | N/A | vs OPTH |
forward FY estimate
N/A
$98701.00
vs Estimate
$154880.00
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$4.20
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | CAD -0.13 | CAD -0.13 | CAD -0.13 | 1 |
| Quarter ending Dec 2026 | CAD -0.13 | CAD -0.13 | CAD -0.13 | 1 |
| Quarter ending Mar 2027 | CAD -0.11 | CAD -0.11 | CAD -0.11 | 1 |
| Quarter ending Jun 2027 | CAD -0.11 | CAD -0.11 | CAD -0.11 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | CAD -1.41 | CAD -1.41 | CAD -1.41 | 1 |
| FY 2027 | CAD -0.64 | CAD -0.64 | CAD -0.64 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | CAD 189621.00 | CAD 189621.00 | CAD 189621.00 | 1 |
| Quarter ending Dec 2026 | CAD 203348.00 | CAD 203348.00 | CAD 203348.00 | 1 |
| Quarter ending Mar 2027 | CAD 210360.00 | CAD 210360.00 | CAD 210360.00 | 1 |
| Quarter ending Jun 2027 | CAD 210360.00 | CAD 210360.00 | CAD 210360.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | CAD 650400.00 | CAD 650400.00 | CAD 650400.00 | 1 |
| FY 2027 | CAD 1.18M | CAD 1.18M | CAD 1.18M | 1 |
